'Lisbon-based Somai Pharmaceuticals, which is involved in the extraction, development and distribution of medical cannabis products, is seeking €250mn as a “reasonable” valuation in a Nasdaq IPO, with a secondary listing on the Toronto Stock Exchange or the LSE, said chief executive Michael Sassano.'

https://www.ft.com/content/e5e099b5-d7c9-4281-b370-79cb437459e6